14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 96 days ( 10.62 % )
Last Price $0.0291 0 %
High/ Low $0.0291 - $0.0291 0%
Chg 7 Days N/A $0.0291 $0.0291
Chg 30 Days N/A $0.0291 $0.0291
Chg 12 mos -97.75 % $1.29 $0.0291
Trend - 3 mos 2.62 % Width: 35.75 %
Trend - 12 mos -51.54 % Width: 316.75 %
Pred. range - 3 mos $0.0223 - $0.0303 -23.15 % - 4.32 %
Pred. range - 12 mos N/A - $0.605 -100.00 % - 1,982.17 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Buy Sep 26, 2022 - 93 days
Long MA avg 12 mos Sell Apr 21, 2022 - 201 days
Short/Long MA avg 12 mos Sell Nov 30, -1 - N/A days
Pivot Short Sell Feb 06, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings. Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; a... CRXT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT